CN116075301A - 西达本胺联合雌激素受体下调剂治疗乳腺癌的用途 - Google Patents
西达本胺联合雌激素受体下调剂治疗乳腺癌的用途 Download PDFInfo
- Publication number
- CN116075301A CN116075301A CN202180050445.9A CN202180050445A CN116075301A CN 116075301 A CN116075301 A CN 116075301A CN 202180050445 A CN202180050445 A CN 202180050445A CN 116075301 A CN116075301 A CN 116075301A
- Authority
- CN
- China
- Prior art keywords
- breast cancer
- estrogen receptor
- fulvestrant
- combined
- regulator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明属于生物医药领域，具体涉及西达本胺联合雌激素受体下调剂和/或降解剂治疗乳腺癌的用途。本发明通过研究发现，在他莫昔芬(或氟维司群)获得性耐药的乳腺癌细胞系中，西达本胺对氟维司群具有显著的协同增敏作用，同时，西达本胺与氟维司群联合用药在来曲唑获得性耐药动物模型中显现出显著的协同疗效。
Description
PCT国内申请，说明书已公开。
Claims (9)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010902194 | 2020-09-01 | ||
| CN202010902194X | 2020-09-01 | ||
| PCT/CN2021/115558 WO2022048527A1 (zh) | 2020-09-01 | 2021-08-31 | 西达本胺联合雌激素受体下调剂治疗乳腺癌的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116075301A true CN116075301A (zh) | 2023-05-05 |
Family
ID=80491607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180050445.9A Pending CN116075301A (zh) | 2020-09-01 | 2021-08-31 | 西达本胺联合雌激素受体下调剂治疗乳腺癌的用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN116075301A (zh) |
| WO (1) | WO2022048527A1 (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106720A (zh) * | 2017-06-23 | 2019-01-01 | 深圳微芯生物科技股份有限公司 | 西达本胺与依西美坦在制备用于治疗乳腺癌的联合用药物中的用途及联合用药物 |
| US20190282541A1 (en) * | 2016-07-20 | 2019-09-19 | Eisai R&D Management Co., Ltd. | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer |
| WO2019199891A1 (en) * | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105541792B (zh) * | 2014-10-22 | 2018-03-13 | 山东轩竹医药科技有限公司 | 多环类pi3k抑制剂 |
| US20190375732A1 (en) * | 2018-05-14 | 2019-12-12 | David Hung | Anti-cancer nuclear hormone receptor-targeting compounds |
-
2021
- 2021-08-31 CN CN202180050445.9A patent/CN116075301A/zh active Pending
- 2021-08-31 WO PCT/CN2021/115558 patent/WO2022048527A1/zh not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190282541A1 (en) * | 2016-07-20 | 2019-09-19 | Eisai R&D Management Co., Ltd. | Use of eribulin and histone deacetylase inhibitors in the treatment of cancer |
| CN109106720A (zh) * | 2017-06-23 | 2019-01-01 | 深圳微芯生物科技股份有限公司 | 西达本胺与依西美坦在制备用于治疗乳腺癌的联合用药物中的用途及联合用药物 |
| WO2019199891A1 (en) * | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
Non-Patent Citations (3)
| Title |
|---|
| WEI LI等: "Chidamide combined with fulvestrant in the treatment of HR-positive and HER2-negative advanced breast cancer after failure of previous endocrine therapy:A single-arm, single-center, phase 2 study", 《CANCER RES》, vol. 83, no. 5, pages 3 - 01 * |
| 只向成等: "西达本胺治疗乳腺肿瘤的研究进展", 《天津医药》, vol. 48, no. 6, pages 567 - 571 * |
| 周游等: "ER阳性乳腺癌中西达本胺逆转内分泌耐药", 《深圳大学学报理工版》, vol. 35, no. 4, pages 339 - 344 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022048527A1 (zh) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Toms et al. | Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial | |
| Kottschade et al. | The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial | |
| Cohen et al. | A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood | |
| JP2014519333A5 (zh) | ||
| CN116075301A (zh) | 西达本胺联合雌激素受体下调剂治疗乳腺癌的用途 | |
| Park et al. | Pattern alopecia during hormonal anticancer therapy in patients with breast cancer | |
| CN115003332A (zh) | 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途 | |
| CN103845701B (zh) | 治疗脚气的外用复方酊剂 | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| CN101780205A (zh) | 用于治疗奶牛乳房炎的中药复方透皮贴剂及制备方法 | |
| Tremblay et al. | Local and systemic effects of a silver nitrate coated indwelling pleural catheter in an animal model of pleurodesis | |
| NO20062904L (no) | Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti | |
| Ornish | It’s time to embrace lifestyle medicine | |
| Harmer | Breast cancer. Part 3: advanced cancer and psychological implications | |
| Kenjaevich et al. | Preclinical study of drug forms based on chitosan | |
| CN109260190A (zh) | 一种用于治疗非糜烂期口腔扁平苔藓和口腔白斑的药物组合物及其应用 | |
| CN107496565A (zh) | 一种治疗甲真菌病的药液及其制备方法和应用 | |
| CN104606295A (zh) | 非抗生素类抗真菌外用药 | |
| Väkevä et al. | Intralesional rituximab treatment for primary cutaneous B-cell lymphoma: Nine finnish cases | |
| McKee et al. | A Randomized and Controlled Comparative Study to Determine the Effectiveness of Long Dan Xie Gan in Combination with Osurnia for the Treatment of Acute Canine Otitis Externa. | |
| Baykulov et al. | PRECLINICAL STUDY NEW OF DRUG FORMS BASED ON CHITOSAN | |
| Rubin et al. | Veterinary Medical Ozone Therapy: An Integrative Approach | |
| CN107823548A (zh) | 一种养生泡脚药包 | |
| Cole | Cancer expert doubts claims about prostate cancer trial | |
| Anupanthumetha | A case report: seminoma induced canine dermatosis in 9-year-old golden retriever. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20230505 |
|
| RJ01 | Rejection of invention patent application after publication |